c-MET / HGFR - SPR Binding Assay

Our service for comprehensive kinetic characterization of your small molecule kinase inhibitors

Theoretical background: c - MET (Mesenchymal epithelial transition factor), also known as hepatocyte growth factor receptor (HGFR) is a receptor tyrosine kinase. The endogenous ligand for c - MET is hepatocyte growth factor/scatter factor (HGF), a disulfide-linked heterodimeric molecule produced predominantly by mesenchymal cells. Ligand-dependent activation of c - MET results in cell proliferation, migration and matrix invasion. These activities facilitate epithelial cell transformation and malignant progression. Thus, abberant activation of the HGF / c - MET pathway leads to a variety of cancers. Amplification of c - MET was also identified as a  mechanism of drug resistance in lung cancer patients initially responsive to the EGFR kinase inhibitors Gefitinib or Erlotinib.


c-MET and inhibitors: SU11274 targets the ATP - binding site of wild type c - MET (IC50 = 20 nM [1]) resulting in an inhibiton of kinase downstream signaling whereas several c - MET mutant forms are resistant to inhibition. AM7, interacting with c - MET in a different binding mode, can bind both the inactive and active form (IC50 = 17 nM [2]) and shows activity against a panel of c - MET mutations found in cancer patients. Crizotinib / PF-2341066 , a multitargeted receptor tyrosine kinase inhibitor, primarily synthesized as ATP - competitive inhibitor for c - MET (IC50 = 11 nM [3]) and ALK is still undergoing clinical trials.

Figure: Real-time kinetic analysis of kinase inhibitor Erlotinib binding to c-MET using surface plasmon resonance.

[1] Sattler M et al.
(2003) Cancer Res. 63(17):5462-9

[2] Bellon SF et al. (2008) J Biol Chem. 283(5):2675-83.

[3] Marion Z et al. (2010) Neoplasia. 12(1): 1–10


Please contact our application specialists to obtain more information and an individual quote tailored to your specific needs.

BIAFFIN GmbH & Co KG | Heinrich-Plett-Str. 40 | D-34132 Kassel | Germany
Tel.: +49 (0) 561-804 4661 | Fax: +49 (0) 561-804 4665 | info@biaffin.de

We value your privacy

In order to optimize our website for you and to be able to continuously improve it, we use cookies. Further information is available in our Data Protection Statement. Here you can find our Legal Information.